Screener
Scholar Rock SRRK Apitegromab — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Scholar Rock in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Scholar Rock’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:20 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336732
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Employee related expense(1) | $37,445 | $32,484 | $74,971 | $55,422 |
| External R&D expense - apitegromab | 22,948 | 27,956 | 43,209 | 47,257 |
| External R&D expense - SRK-181 | 9 | 792 | 45 | 1,902 |
| External R&D expense - SRK-439 | 3,760 | 2,575 | 5,519 | 6,854 |
| External R&D expense - Early research and other | 1,610 | 2,227 | 2,820 | 3,682 |
| External expense - G&A | 16,597 | 14,952 | 32,729 | 23,895 |
| Other segment items(2) | 6,573 | 6,273 | 13,082 | 11,531 |
Item 1. Financial Statements
FAQ
- What is Scholar Rock's apitegromab — research and development expense?
- Scholar Rock (SRRK) reported apitegromab — research and development expense of $22.95M in Q2 2026.
- How has Scholar Rock's apitegromab — research and development expense changed year-over-year?
- Scholar Rock's apitegromab — research and development expense decreased by 17.9% year-over-year, from $27.96M to $22.95M.
- What does apitegromab — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the Apitegromab product candidate. It captures the investment intensity required to progress this specific therapeutic asset through clinical trials and toward potential commercialization. Monitoring this expense helps investors assess the company's capital allocation strategy and the financial commitment dedicated to its primary pipeline asset.
Ask your AI about Scholar Rock's apitegromab — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude